Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
HardwareX ; 102021 Oct.
Article in English | MEDLINE | ID: mdl-34734152

ABSTRACT

Neuromonitoring in naturalistic environments is of increasing interest for a variety of research fields including psychology, economics, and productivity. Among functional neuromonitoring modalities, functional near-infrared spectroscopy (fNIRS) is well regarded for its potential for miniaturization, good spatial and temporal resolutions, and resilience to motion artifacts. Historically, the large size and high cost of fNIRS systems have precluded widespread adoption of the technology. In this article, we describe the first open source, fully integrated wireless fNIRS headband system with a single LED-pair source and four detectors. With ease of operation and comfort in mind, the system is encased in a soft, lightweight cloth and silicone enclosure. Accompanying computer and smartphone data collection software have also been provided, and the hardware has been validated using classic fNIRS tasks. This wear-and-go design can easily be scaled to accommodate a larger number of fNIRS channels and opens the door to easily collecting fNIRS data during routine activities in naturalistic conditions.

2.
Cancer Med ; 10(18): 6249-6260, 2021 09.
Article in English | MEDLINE | ID: mdl-34390226

ABSTRACT

OBJECTIVE: Previous research has indicated cognitive decline (CD) among testicular cancer patients (TCPs), even in the absence of chemotherapy, but little is known about the underlying pathophysiology. The present study assessed changes in cognitive functions and structural brain connectomes in TCPs and explored the associations between cognitive changes and endocrine status and hypothesized risk genotypes. METHODS: Thirty-eight newly orchiectomized TCPs and 21 healthy controls (HCs) comparable to TCPs in terms of age and years of education underwent neuropsychological testing, structural MRI, and a biological assessment at baseline and 6 months later. Cognitive change was assessed with a neuropsychological test battery and determined using a standardized regression-based approach, with substantial change defined as z-scores ≤-1.64 or ≥1.64. MRI scans and graph theory were used to evaluate changes in structural brain connectomes. The associations of cognitive changes with testosterone levels, androgen receptor gene (AR) CAG repeat length, and genotypes (APOE, COMT, and BDNF) were explored. RESULTS: Compared with HCs, TCPs showed higher rates of substantial decline on processing speed and visuospatial ability and higher rates of substantial improvement on verbal recall and visuospatial learning (p < 0.05; OR = 8.15-15.84). Brain network analysis indicated bilateral thalamic changes in node degree in HCs, but not in TCPs (p < 0.01). In TCPs, higher baseline testosterone levels predicted decline in verbal memory (p < 0.05). No effects were found for AR CAG repeat length, APOE, COMT, or BDNF. CONCLUSIONS: The present study confirms previous findings of domain-specific CD in TCPs following orchiectomy, but also points to domain-specific improvements. The results do not indicate changes in brain connectomes or endocrine status to be the main drivers of CD. Further studies evaluating the mechanisms underlying CD in TCPs, including the possible role of the dynamics of the hypothalamic-pituitary-gonadal axis, are warranted.


Subject(s)
Brain/physiopathology , Cognitive Dysfunction/physiopathology , Orchiectomy/adverse effects , Testicular Neoplasms/surgery , Adult , Brain/diagnostic imaging , Case-Control Studies , Cognition , Cognitive Dysfunction/diagnosis , Cognitive Dysfunction/genetics , Cognitive Dysfunction/metabolism , Connectome , Healthy Volunteers , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Neuropsychological Tests/statistics & numerical data , Prospective Studies , Receptors, Androgen/genetics , Testicular Neoplasms/blood , Testicular Neoplasms/genetics , Testicular Neoplasms/psychology , Testis/metabolism , Testis/pathology , Testis/surgery , Testosterone/blood , Testosterone/metabolism , Young Adult
3.
J Psychopharmacol ; 33(8): 975-985, 2019 08.
Article in English | MEDLINE | ID: mdl-31264943

ABSTRACT

BACKGROUND: Fragile X syndrome, the most common inherited cause for intellectual disability, is associated with alterations in cholinergic among other neurotransmitter systems. This study investigated the effects of donepezil hydrochloride, a cholinesterase inhibitor that has potential to correct aberrant cholinergic signaling. METHOD: Forty-two individuals with fragile X syndrome (mean age=19.61 years) were randomized to receive 2.5-10.0 mg of donepezil (n=20, seven females) or placebo (n=22, eight females) per day. One individual in the active group withdrew at week 7. Outcomes included the contingency naming test, the aberrant behavior checklist, and behavior and brain activation patterns during a functional magnetic resonance imaging gaze discrimination task. RESULTS: There were no significant differences between active and placebo groups on cognitive (contingency naming task) or behavioral (total score or subscales of the aberrant behavior checklist) outcomes. At baseline, the active and placebo groups did not differ in functional magnetic resonance imaging activation patterns during the gaze task. After 12 weeks of treatment the active group displayed reduced activation in response to the averted vs direct gaze contrast, relative to the placebo group, in the left superior frontal gyrus. CONCLUSIONS: Reduced functional brain activation for the active group may represent less arousal in response to direct eye gaze, relative to the placebo group. Change in functional magnetic resonance imaging activation patterns may serve as a more sensitive metric and predictor of response to treatment when compared to cognitive and behavioral assessments. Our results suggest that donepezil may have an impact on brain functioning, but longer term follow-up and concomitant behavioral intervention may be required to demonstrate improvement in cognition and behavior.


Subject(s)
Brain/drug effects , Cholinesterase Inhibitors/therapeutic use , Cognition Disorders/drug therapy , Cognition/drug effects , Donepezil/therapeutic use , Fragile X Syndrome/drug therapy , Nootropic Agents/therapeutic use , Adolescent , Adult , Child , Female , Humans , Magnetic Resonance Imaging/methods , Male , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...